EP300 and prostate carcinoma: Since activation of p300/CBP was reported in colorectal, breast, and prostate cancer, this signal activation may be directly associated with tumorigenesis [23, 24], however, it remains unclear whether inactivation of p300/CBP by HAT inhibitors may be suppress the proliferation and migration of normal or cancer cells.